ReviewNanomaterials (Basel, Switzerland)2017
Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer.
Review in Nanomaterials (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
150 citing papers in PubMed.
- Pharmacological features of mesoionic compounds: antitumoral effects and bioenergetic disruption of sydnones and 1,3,4-thiadiazolium derivatives.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Investigation of the cytotoxic and apoptotic effects of propylthiouracil-loaded mesoporous nanoparticles on Ehrlich ascites tumor cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Dual-Stimuli Responsive Cystamine-Modified Polydopamine Coatings as Payload Gatekeepers.Molecules (Basel, Switzerland) · 2026Article
- Hollow Mesoporous Silica Nanoparticles Co-Loaded with Docetaxel and Indocyanine Green for Synergistic Chemo-Photothermal Therapy.Nanomaterials (Basel, Switzerland) · 2026Article
- CD44 Targeting of Cisplatin-Loaded Hyaluronic Acid-Modified Mesoporous Silica Nanoparticles for Lung Adenocarcinoma: Synthesis, Characterization, In Vitro and In Vivo Evaluation.Pharmaceutics · 2026Article
- Targeted immunotherapies and nanomedicines for ovarian cancer: the way forward.NPJ precision oncology · 2026Review
- Using silica nanoparticles to deliver antibiotics for treating Gram-positive bacterial infections in a 3D-bioprinted dermal model.Frontiers in bioengineering and biotechnology · 2026Article
- Programmable nanocarriers for precision plant engineering: converging nanotechnology, CRISPR, and next-generation breeding.Frontiers in plant science · 2026Review
- Hybrid Platinum(IV)-Naproxen Nanostructured Drugs Reprogram Melanoma Cells and Overpower Cisplatin.Nanomaterials (Basel, Switzerland) · 2025Article
- pH-Responsive Hollow Mesoporous Silica Nanoparticles with Fludarabine for Cancer Therapy.Nanomaterials (Basel, Switzerland) · 2025Article
- Applications of Tailored Mesoporous Silicate Nanomaterials in Regenerative Medicine and Theranostics.International journal of molecular sciences · 2025Review
- Macrophages co-loaded with drug-associated and superparamagnetic nanoparticles for triggered drug release by alternating magnetic fields.Drug delivery and translational research · 2025Article
- Nanocarriers for Combination Therapy in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.Nanomaterials (Basel, Switzerland) · 2025Review
- A Review on the Recent Advancements of Polymer-Modified Mesoporous Silica Nanoparticles for Drug Delivery Under Stimuli-Trigger.Polymers · 2025Review
- Peptide-based drugs in immunotherapy: current advances and future prospects.Medical oncology (Northwood, London, England) · 2025Review
- Photoresponsive Luminescent Silica Nanoparticles as Additive for 3D Printing and Electrospinning.Chemistry, an Asian journal · 2025Article
- Lipid-Coated Mesoporous Silica Particles for pH-Sensitive Tumor-Targeted Paclitaxel: Development, Characterization.Journal of Cancer · 2025Article
- Nuclei-targeted Therapeutic Delivery: A Novel Concept for the Treatment of Cancer.Mini reviews in medicinal chemistry · 2025Article
- Dynamic-Covalent Mesoporous Silica Nanohybrid with pH/ROS-Responsive Drug Release for Targeted Tumor Therapy.ACS omega · 2024Article
- Porous silicon and silica carriers for delivery of peptide therapeutics.Drug delivery and translational research · 2024Review
90 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Even though cancer treatment has improved over the recent decades, still more specific and effective treatment concepts are mandatory. Surgical removal is not always possible, metastases are challenging and chemo- and radiotherapy can not only have severe side-effects but also resistances may occur. To cope with these challenges more efficient therapies with fewer side-effects are required. One promising approach is the use of drug delivery vehicles. Here, mesoporous silica nanoparticles (MSN) are discussed as biodegradable drug carrier to improve efficacy and reduce side-effects. MSN excellently fulfill the criteria for nanoparticulate carriers: their distinct structure allows high loading capacity and a plethora of surface modifications. MSN synthesis permits fine-tuning of particle and pore sizes. Moreover, drug release can be tailored through various gatekeeper systems which are for example pH-sensitive or redox-sensitive. Furthermore, MSN can either enter tumors passively by the enhanced permeability and retention effect or can be actively targeted by various ligands. PEGylation prolongs circulation time and availability. A huge advantage of MSN is their explicitly low toxic profile in vivo. Yet, clinical translation remains challenging. Overall, mesoporous silica nanoparticles are a promising tool for innovative, more efficient and safer cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.